London, United Kingdom
Oxford Pharmascience Ltd, founded in 2008, is a UK-based company leading innovations in the pharmaceutical industry. Specializing in the development of next-generation oral delivery systems, their flagship technology, the Oxprofen™ platform, utilizes a proprietary layered double hydroxide (LDH) formulation of ibuprofen. This advancement ensures rapid onset of pain relief, enhanced tolerability, and effective taste masking.
By leveraging partnerships with top over-the-counter and prescription companies, Oxford Pharmascience Ltd is positioning its analgesic products for success in global markets. With a focus on advanced pain relief technologies that promise fast action and better patient compliance, the company stands out in the Biotechnology and Pharmaceutical sectors.
Despite a robust foundation and strategic industry partnerships, it appears the company has not disclosed any recent investment activity, which may present an intriguing opportunity for stakeholders seeking innovation in pain management solutions.
